Generic Aerospan HFA Availability
AEROSPAN HFA (flunisolide - aerosol, metered;inhalation)
Manufacturer: MEDA PHARMS INC
Approval date: January 27, 2006
Strength(s): 0.078MG/INH [RLD]
Has a generic version of Aerospan HFA been approved?
No. There is currently no therapeutically equivalent version of Aerospan HFA available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Aerospan HFA. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Flunisolide aerosol formulations
Issued: July 7, 1998
Inventor(s): Tzou; Tsi-Zong & Schultz; Robert K. & Ross; Danna L.
Assignee(s): Minnesota Mining and Manufacturing Company
Pharmaceutical aerosol formulations substantially free of chlorofluorocarbons and comprising a therapeutically effective amount of flunisolide in solution with ethanol and a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane and a mixture thereof are used for the treatment of bronchial asthma. The formulation may be delivered by a metered dose inhaler with a canister that is inert to flunisolide.Patent expiration dates:
- July 7, 2015✓
- July 7, 2015
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- August 28, 2016 - CLINICAL TRIAL STUDY RESULTS
- Aerospan aerosol inhaler Consumer Information (Wolters Kluwer)
- Aerospan hfa inhaler Consumer Information (Wolters Kluwer)
- Aerospan Consumer Information (Cerner Multum)
- Aerospan Advanced Consumer Information (Micromedex®)
- Aerospan AHFS DI Monographs (ASHP)
- Flunisolide aerosol inhaler Consumer Information (Wolters Kluwer)
- Flunisolide hfa inhaler Consumer Information (Wolters Kluwer)
- Flunisolide inhalation Consumer Information (Cerner Multum)
- Flunisolide Inhalation Advanced Consumer Information (Micromedex®)
- Flunisolide AHFS DI Monographs (ASHP)
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|